Clinicians who treat patients with acromegaly commonly show a lack of awareness of the severity and pattern of patient symptoms that can occur even when treatment suggests the condition is under ...

Please provide your email address to receive an email when new articles are posted on . One-third of acromegaly and growth hormone deficiency studies report discrepancies between patient-reported ...

Redefining Acromegaly Care: First Patient Randomized in Debiopharm’s Phase III OXTEND-03™ Trial of 3-Month Debio 4126 Treatment OXTEND-03™ (NCT06930625) is a Phase III, multi-center, randomized trial ...

Crinetics Pharmaceuticals develops therapeutics for endocrine diseases and tumors. Its lead drug candidate, paltusotine, is undergoing two Phase 3 trials for acromegaly treatment. In acromegaly, the ...

- If successful, paltusotine would offer acromegaly patients a once-daily oral treatment option - SAN DIEGO, June 28, 2021 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a ...

MONTREAL, Sept. 27, 2018 /CNW Telbec/ - A rare condition gets the chance to shine tonight through the power of collective art, as patient stories celebrate struggles and successes with acromegaly. At ...

The FDA has approved an oral treatment to help people diagnosed with a rare overgrowth disease. Oregon resident, Stacey Hardin says news about the therapeutic advancement is “huge” and could mean an ...

Optimal biochemical control cannot be attained by long-acting somatostatin analog monotherapy in a large proportion of patients with acromegaly. Such therapy might result in increased mortality, poor ...

The FDA has approved Mycapssa® (octreotide; Chiasma) capsules for the long-term maintenance treatment in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide ...

Acromegaly is one of those diseases that immediately caught our attention when we first heard about it in medical school. We stared at the textbook pictures of big hands and coarse faces—maybe a very ...

OXTEND-03™ (NCT06930625) is a Phase III, multi-center, randomized trial assessing the efficacy and safety of Debio 4126, the first and only octreotide formulation designed for quarterly (3-month) ...